"It would not be surprising if we saw longer review times, at least in the near term," Shuren said about the FDA layoffs.
Vivex Biologics chairman John McCallum breaks down the challenges, costs, and strategies behind bringing medical innovations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback